We are live on
!
Find out more
FCM
Findell Capital Management Portfolio holdings
AUM
$340M
1-Year Est. Return
135.6%
This Fund
S&P 500
1 Year Est. Return
+135.6%
AUM
$340M
AUM Growth
+$38.6M
(+13%)
Holding
20
Top Buys
| 1 | +$24.1M | |
| 2 | +$19.4M | |
| 3 | +$8.17M | |
| 4 |
Cenovus Energy
CVE
|
+$8M |
| 5 |
Acadia Healthcare
ACHC
|
+$6.88M |
Top Sells
| 1 | +$9.06M | |
| 2 | +$5.84M | |
| 3 | +$5.47M | |
| 4 |
Turning Point Brands
TPB
|
+$3.57M |
| 5 |
Vor Biopharma
VOR
|
+$3.02M |
Sector Composition
| 1 | Healthcare | 63.28% |
| 2 | Technology | 9.9% |
| 3 | Financials | 8.68% |
| 4 | Consumer Discretionary | 4.77% |
| 5 | Consumer Staples | 4.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$7.04B
| $132M | 38.93% |
3,502,112
+650,663
|
|
||
2
Establishment Labs
ESTA
$2.69B
| $56.7M | 16.68% |
997,747
-132,713
|
|
||
3
Dave Inc
DAVE
$5.03B
| $29.6M | 8.72% |
170,000
+100,000
|
|
||
4
Root
ROOT
$1.01B
| $16.6M | 4.88% |
375,000
+140,000
|
|
||
5
SGHC Ltd
SGHC
$7.45B
| $16.2M | 4.77% |
1,500,000
+560,000
|
|
||
6
The GEO Group
GEO
$3.97B
| $14.7M | 4.33% |
875,000
+225,000
|
|
||
7
Oportun Financial
OPRT
$268M
| $12.7M | 3.73% |
2,748,300
+180,000
|
|
||
|
ABVX
8
Abivax
ABVX
$11.5B
| $11.7M | 3.44% |
105,000
+57,000
|
|
||
|
9
Cenovus Energy
CVE
$45.4B
| $9.95M | 2.93% |
+375,000
|
|
||
|
10
Acadia Healthcare
ACHC
$2.86B
| $8.89M | 2.62% |
+380,000
|
|
||
|
11
Turning Point Brands
TPB
$1.66B
| $8.25M | 2.43% |
95,000
-32,000
|
|
||
12
Celsius Holdings
CELH
$8.45B
| $7.1M | 2.09% |
200,000
-10,000
|
|
||
13
Mineralys Therapeutics
MLYS
$2.57B
| $5.47M | 1.61% |
202,000
+152,000
|
|
||
14
Vermilion Energy
VET
$1.34B
| $5.1M | 1.5% |
+370,000
|
|
||
15
Applied Digital
APLD
$9.57B
| $4.04M | 1.19% |
+170,000
|
|
||
16
Peabody Energy
BTU
$2.76B
| $276K | 0.08% |
+8,381
|
|
||
17
eHealth
EHTH
$53.6M
| $231K | 0.07% |
179,027
-1,229,948
|
|
||
18
ADMA Biologics
ADMA
$2.12B
| – | – |
-300,000
|
|
||
19
Stride
LRN
$3.84B
| – | – |
-90,000
|
|
||
|
20
Vor Biopharma
VOR
$1.09B
| – | – |
-231,000
|
|